

# Zhenfeng Duan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1089463/zhenfeng-duan-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

139  
papers

5,098  
citations

38  
h-index

64  
g-index

143  
ext. papers

5,996  
ext. citations

6.5  
avg, IF

5.78  
L-index

#	Paper	IF	Citations
139	SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma.. <i>Bioscience Reports</i> , <b>2022</b> ,	4.1	2
138	High miR-3609 expression is associated with better prognosis in TNBC based on mining using systematic integrated public sequencing data.. <i>Experimental and Therapeutic Medicine</i> , <b>2022</b> , 23, 54	2.1	
137	Long noncoding RNA and bone sarcoma <b>2022</b> , 471-485		
136	regulates tumorigenesis and tumor immunity by targeting PD-L1/CCND1 in breast cancer.. <i>Annals of Translational Medicine</i> , <b>2022</b> , 10, 203	3.2	2
135	Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma.. <i>Biomedicine and Pharmacotherapy</i> , <b>2022</b> , 149, 112888	7.5	
134	ATR inhibition sensitizes liposarcoma to doxorubicin by increasing DNA damage.. <i>American Journal of Cancer Research</i> , <b>2022</b> , 12, 1577-1592	4.4	
133	Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 644857	5.3	0
132	Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation. <i>Cancer Letters</i> , <b>2021</b> , 505, 37-48	9.9	7
131	T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma. <i>Molecular Oncology</i> , <b>2021</b> , 15, 3721-3737	7.9	1
130	Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X21995069	3.8	1
129	Advances in the Molecular Biology of Chondrosarcoma <b>2021</b> , 27-52		
128	Myc is a prognostic biomarker and potential therapeutic target in osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920922055	5.4	22
127	Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma. <i>Journal of Orthopaedic Research</i> , <b>2020</b> , 38, 1952-1964	3.8	10
126	Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. <i>Cancer Letters</i> , <b>2020</b> , 474, 158-167	9.9	30
125	ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920982853	5.4	5
124	Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application. <i>Cancer Letters</i> , <b>2020</b> , 479, 54-60	9.9	14
123	Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067. <i>Journal of Cancer</i> , <b>2020</b> , 11, 132-141	4.5	5

122	Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777. <i>Journal of Orthopaedic Research</i> , <b>2020</b> , 38, 902-910	3.8	4
121	Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 82, 101934	14.4	32
120	Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920956900	5.1	6
119	Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value. <i>European Spine Journal</i> , <b>2020</b> , 29, 3214-3228	2.7	1
118	Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 596330	5.3	0
117	The role of extracellular matrix in osteosarcoma progression and metastasis. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 178	12.8	23
116	T-LAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma. <i>Cell Proliferation</i> , <b>2020</b> , 53, e12901	7.9	5
115	PTEN in osteosarcoma: Recent advances and the therapeutic potential. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2020</b> , 1874, 188405	11.2	19
114	Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. <i>Journal of Orthopaedic Research</i> , <b>2020</b> , 38, 2362-2372	3.8	5
113	Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma. <i>Journal of Orthopaedic Research</i> , <b>2019</b> , 37, 789-798	3.8	17
112	Crystallization and characterization of small molecular multidrug resistance inhibitor targeting P-glycoprotein, NSC23925 isomers. <i>Journal of Molecular Structure</i> , <b>2019</b> , 1193, 7-13	3.4	
111	Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: Therapeutic potential of targeting the CDK signaling pathway. <i>Hepatology Research</i> , <b>2019</b> , 49, 1097-1108	5.1	18
110	miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint. <i>Experimental Cell Research</i> , <b>2019</b> , 380, 20-28	4.2	31
109	Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer. <i>FASEB Journal</i> , <b>2019</b> , 33, 5990-6000	0.9	29
108	Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 979-993	7.5	48
107	Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , <b>2019</b> , 15, 100221	4.5	69
106	Exosomes promote pre-metastatic niche formation in ovarian cancer. <i>Molecular Cancer</i> , <b>2019</b> , 18, 124	42.1	106
105	Transcriptional activation of CBF $\beta$ by CDK11 is necessary to promote osteosarcoma cell proliferation. <i>Cell Communication and Signaling</i> , <b>2019</b> , 17, 125	7.5	6

104	Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. <i>EBioMedicine</i> , <b>2019</b> , 39, 182-193	8.8	47
103	Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. <i>Journal of Orthopaedic Research</i> , <b>2019</b> , 37, 510-521	3.8	9
102	RNA sequencing (RNA-Seq) and its application in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 194-201	4.9	47
101	Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma. <i>Cell Death and Disease</i> , <b>2018</b> , 9, 446	9.8	16
100	CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells. <i>Cellular Physiology and Biochemistry</i> , <b>2018</b> , 46, 1218-1230	3.9	20
99	Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer. <i>Gynecologic Oncology</i> , <b>2018</b> , 150, 143-150	4.9	18
98	Expression and Clinical Implication of Autophagy-Associated Protein p62 in Osteosarcoma. <i>Oncology</i> , <b>2018</b> , 95, 52-60	3.6	4
97	Expression and therapeutic implications of cyclin-dependent kinase 4 (CDK4) in osteosarcoma. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2018</b> , 1864, 1573-1582	6.9	25
96	Advances in chromosomal translocations and fusion genes in sarcomas and potential therapeutic applications. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 63, 61-70	14.4	19
95	Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells. <i>Oncotarget</i> , <b>2018</b> , 9, 13154-13166	3.3	8
94	An Update on Circumventing Multidrug Resistance in Cancer by Targeting P-Glycoprotein. <i>Current Cancer Drug Targets</i> , <b>2018</b> , 18, 677-696	2.8	9
93	CDK4 expression in chordoma: A potential therapeutic target. <i>Journal of Orthopaedic Research</i> , <b>2018</b> , 36, 1581-1589	3.8	13
92	Application of liquid biopsy in bone and soft tissue sarcomas: Present and future. <i>Cancer Letters</i> , <b>2018</b> , 439, 66-77	9.9	25
91	From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma. <i>Cancer and Metastasis Reviews</i> , <b>2018</b> , 37, 719-731	9.6	31
90	miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo. <i>Molecular Oncology</i> , <b>2017</b> , 11, 151-166	7.9	36
89	Autophagy as a potential target for sarcoma treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2017</b> , 1868, 40-50	11.2	15
88	Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosis. <i>Cellular Oncology (Dordrecht)</i> , <b>2017</b> , 40, 209-218	7.2	25
87	Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. <i>Scientific Reports</i> , <b>2017</b> , 7, 43941	4.9	8

86	Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 1580	4.9	12
85	Expression and Therapeutic Potential of SOX9 in Chordoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5176-5186	6.9	29
84	Regulation of microRNA-1 (miR-1) expression in human cancer. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , <b>2017</b> , 1860, 227-232	6	28
83	Regulation of microRNAs function by circular RNAs in human cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 64622-64637	3.3	40
82	Three-dimensional (3D) culture in sarcoma research and the clinical significance. <i>Biofabrication</i> , <b>2017</b> , 9, 032003	10.5	19
81	Application of metabolomics in sarcoma: From biomarkers to therapeutic targets. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 116, 1-10	7	8
80	Therapeutic applications of histone deacetylase inhibitors in sarcoma. <i>Cancer Treatment Reviews</i> , <b>2017</b> , 59, 33-45	14.4	36
79	An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 107	22.4	26
78	Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 84559-84571	3.3	93
77	Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	24
76	Aberration of Promoter Methylation in Chondrosarcoma. <i>Anticancer Research</i> , <b>2017</b> , 37, 2939-2945	2.3	3
75	MicroRNA-7 regulates IL-1 $\beta$ induced extracellular matrix degeneration by targeting GDF5 in human nucleus pulposus cells. <i>Biomedicine and Pharmacotherapy</i> , <b>2016</b> , 83, 1414-1421	7.5	29
74	Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats. <i>Scientific Reports</i> , <b>2016</b> , 6, 25659	4.9	11
73	Matrine induces cell cycle arrest and apoptosis with recovery of the expression of miR-126 in the A549 non-small cell lung cancer cell line. <i>Molecular Medicine Reports</i> , <b>2016</b> , 14, 4042-4048	2.9	47
72	Aberrant DNA methylations in chondrosarcoma. <i>Epigenomics</i> , <b>2016</b> , 8, 1519-1525	4.4	16
71	Clinical and biological significance of PIM1 kinase in osteosarcoma. <i>Journal of Orthopaedic Research</i> , <b>2016</b> , 34, 1185-94	3.8	13
70	The roles and implications of exosomes in sarcoma. <i>Cancer and Metastasis Reviews</i> , <b>2016</b> , 35, 377-90	9.6	26
69	NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. <i>British Journal of Pharmacology</i> , <b>2016</b> , 173, 613-26	8.6	23

68	Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma. <i>Cancer Letters</i> , <b>2016</b> , 373, 109-118	9.9	24
67	The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. <i>Cancer and Metastasis Reviews</i> , <b>2016</b> , 35, 151-63	9.6	22
66	Targeting protein kinases to reverse multidrug resistance in sarcoma. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 43, 8-18	14.4	18
65	p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 349-56	3.5	26
64	Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential. <i>Oncotarget</i> , <b>2016</b> , 7, 38333-38346	3.3	44
63	The Roles of Sox Family Genes in Sarcoma. <i>Current Drug Targets</i> , <b>2016</b> , 17, 1761-1772	3	19
62	The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 40846-40859	3.3	36
61	Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray. <i>Journal of Orthopaedic Research</i> , <b>2016</b> , 34, 1606-12	3.8	11
60	Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro. <i>Scientific Reports</i> , <b>2016</b> , 6, 25239	4.9	33
59	Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1691-701	6.1	24
58	CSPG4 as a prognostic biomarker in chordoma. <i>Spine Journal</i> , <b>2016</b> , 16, 722-7	4	21
57	Novel mechanisms and approaches to overcome multidrug resistance in the treatment of ovarian cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , <b>2016</b> , 1866, 266-275	11.2	54
56	CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. <i>Scientific Reports</i> , <b>2015</b> , 5, 11365	4.9	55
55	NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo. <i>Gynecologic Oncology</i> , <b>2015</b> , 137, 134-42	4.9	9
54	MicroRNA-1 (miR-1) inhibits gastric cancer cell proliferation and migration by targeting MET. <i>Tumor Biology</i> , <b>2015</b> , 36, 6715-23	2.9	50
53	Near-infrared light activated delivery platform for cancer therapy. <i>Advances in Colloid and Interface Science</i> , <b>2015</b> , 226, 123-37	14.3	33
52	Selective enhancement of red emission from upconversion nanoparticles via surface plasmon-coupled emission. <i>RSC Advances</i> , <b>2015</b> , 5, 76825-76835	3.7	22
51	Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system. <i>Journal of Orthopaedic Research</i> , <b>2015</b> , 33, 199-207	3.8	50

50	Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 2029-39	7.5	20
49	Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells. <i>International Journal of Nanomedicine</i> , <b>2015</b> , 10, 2913-24	7.3	24
48	Rhabdomyosarcoma: Advances in Molecular and Cellular Biology. <i>Sarcoma</i> , <b>2015</b> , 2015, 232010	3.1	45
47	Distance-dependent plasmon-enhanced fluorescence of upconversion nanoparticles using polyelectrolyte multilayers as tunable spacers. <i>Scientific Reports</i> , <b>2015</b> , 5, 7779	4.9	144
46	Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth. <i>Scientific Reports</i> , <b>2015</b> , 5, 10433	4.9	36
45	MicroRNA-155 expression is independently predictive of outcome in chordoma. <i>Oncotarget</i> , <b>2015</b> , 6, 9125-39	3.3	30
44	In vitro effects of mitomycin C on the proliferation of the non-small-cell lung cancer line A549. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2015</b> , 8, 20516-23		7
43	The emerging roles and therapeutic potential of microRNAs (miRs) in liposarcoma. <i>Discovery Medicine</i> , <b>2015</b> , 20, 311-24	2.5	8
42	Synthesis of upconversion NaYF <sub>4</sub> :Yb <sup>3+</sup> ,Er <sup>3+</sup> particles with enhanced luminescent intensity through control of morphology and phase. <i>Journal of Materials Chemistry C</i> , <b>2014</b> , 2, 3671-3676	7.1	54
41	MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug. <i>Journal of Orthopaedic Research</i> , <b>2014</b> , 32, 1075-82	3.8	38
40	Programmed cell death ligand 1 expression in osteosarcoma. <i>Cancer Immunology Research</i> , <b>2014</b> , 2, 690-698	6.8	135
39	Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e93996	3.7	16
38	Role of microRNA-1 in human cancer and its therapeutic potentials. <i>BioMed Research International</i> , <b>2014</b> , 2014, 428371	3	51
37	Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. <i>Oncolmmunology</i> , <b>2014</b> , 3, e954467	7.2	13
36	Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma. <i>Journal of Orthopaedic Research</i> , <b>2014</b> , 32, 695-701	3.8	33
35	A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. <i>BMC Cancer</i> , <b>2014</b> , 14, 681	4.8	16
34	Cyclin-dependent kinase 11 (CDK11) is crucial in the growth of liposarcoma cells. <i>Cancer Letters</i> , <b>2014</b> , 342, 104-12	9.9	41
33	Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1. <i>PLoS ONE</i> , <b>2014</b> , 9, e101283	3.7	60



32	Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma. <i>PLoS ONE</i> , <b>2013</b> , 8, e75851	3.7	31
31	Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. <i>Journal of Medicinal Chemistry</i> , <b>2012</b> , 55, 3113-21	8.3	35
30	Recent advances in synthesis and surface modification of lanthanide-doped upconversion nanoparticles for biomedical applications. <i>Biotechnology Advances</i> , <b>2012</b> , 30, 1551-61	17.8	260
29	Interleukin-6 signaling pathway in targeted therapy for cancer. <i>Cancer Treatment Reviews</i> , <b>2012</b> , 38, 904-104	14	475
28	Establishment and characterization of a novel chordoma cell line: CH22. <i>Journal of Orthopaedic Research</i> , <b>2012</b> , 30, 1666-73	3.8	29
27	High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. <i>Cancer</i> , <b>2012</b> , 118, 2905-14	6.4	58
26	Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4580-8	12.9	51
25	Nanoparticles: a promising modality in the treatment of sarcomas. <i>Pharmaceutical Research</i> , <b>2011</b> , 28, 260-72	4.5	12
24	MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. <i>Molecular Cancer Therapeutics</i> , <b>2011</b> , 10, 1337-45	6.1	211
23	Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5759-69	12.9	77
22	Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma. <i>Cancer Letters</i> , <b>2010</b> , 293, 220-9	9.9	50
21	Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma. <i>Spine</i> , <b>2010</b> , 35, 1668-75	3.3	33
20	Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. <i>BMC Cancer</i> , <b>2010</b> , 10, 187	4.8	49
19	Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression. <i>Journal of Orthopaedic Research</i> , <b>2010</b> , 28, 746-52	3.8	72
18	ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines. <i>PLoS ONE</i> , <b>2009</b> , 4, e6967	3.7	13
17	NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. <i>PLoS ONE</i> , <b>2009</b> , 4, e7415	3.7	37
16	Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 2122-30	6.1	67
15	CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 681-9	3.5	62



14	Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 1121-9	3.5	16
13	RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 64, 607-14	3.5	13
12	Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 2377-85	6.1	26
11	Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2007</b> , 450, 187-94	5.1	18
10	8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells. <i>Molecular Pharmacology</i> , <b>2007</b> , 72, 1137-45	4.3	34
9	GBP1 overexpression is associated with a paclitaxel resistance phenotype. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2006</b> , 57, 25-33	3.5	42
8	Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5055-63	12.9	204
7	SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 6844-52	12.9	64
6	Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2005</b> , 55, 277-85	3.5	64
5	MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines. <i>Gene</i> , <b>2004</b> , 340, 53-9	3.8	12
4	Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2004</b> , 3, 833-8	6.1	115
3	Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 2778-85	12.9	94
2	cDNA Technologies and their application to drug resistance research: power, potential and problems. <i>Drug Resistance Updates</i> , <b>2000</b> , 3, 277-282	23.2	4
1	TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line. <i>Gene</i> , <b>1999</b> , 229, 75-81	3.8	68